YU238259 is a novel inhibitor of homology-dependent DNA repair that exhibits synthetic lethality and radiosensitization in repair-deficient tumors

Molecular Cancer Research

Volumn 13, Issue 10, 2015, Pages 1389-1397

  Stachelek, Gregory C ^a   Peterson Roth, Elizabeth ^a   Liu, Yanfeng ^a   Fernandez, Rafael J ^a   Pike, Luke R G ^a   Qian, Jack M ^a   Abriola, Laura ^b   Hoyer, Denton ^b   Hungerford, William ^b   Merkel, Janie ^b   Glazer, Peter M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; ETOPOSIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; YU 238259; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; INTERCALATING AGENT; MOLECULAR LIBRARY; SULFONAMIDE; YU238259;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DNA SYNTHESIS INHIBITION; DOUBLE STRANDED DNA BREAK; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IONIZING RADIATION; LETHALITY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REPAIR DEFICIENT TUMOR; TUMOR XENOGRAFT; ANIMAL; BONE NEOPLASMS; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; GLIOMA; MOLECULAR LIBRARY; NEOPLASMS; NUDE MOUSE; OSTEOSARCOMA; PHARMACOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BONE NEOPLASMS; CELL LINE, TUMOR; CIRCULAR DICHROISM; COLORECTAL NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DRUG SYNERGISM; ETOPOSIDE; GLIOMA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTERCALATING AGENTS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASMS; OSTEOSARCOMA; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RADIATION-SENSITIZING AGENTS; SMALL MOLECULE LIBRARIES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945257912     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0036     Document Type: Article

References (36)

1. Ginsburg GS. Realizing the opportunities of genomics in health care. JAMA 2013;309:1463-4.
2. Leibeling D, Laspe P, Emmert S. Nucleotide excision repair and cancer. J Mol Histol 2006;37:225-38.
3. Klein TJ, Glazer PM. The tumor microenvironment and DNA repair. Semin Radiat Oncol 2010;20:282-7.
4. Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 2010;16:5107-13.
5. Wallace SS, Murphy DL, Sweasy JB. Base excision repair and cancer. Cancer letters 2012;327:73-89.
6. Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 2013;5:pii: a012716.
7. Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res 2014;12:381-93.
8. Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 2013;32: 577-88.
9. Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol 2014;133:599-606.
10. Lok BH, Carley AC, Tchang B, Powell SN. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene 2013;32:3552-8.
11. Illuzzi JL, Wilson DM 3rd. Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms. Curr Med Chem 2012;19:3922-36.
12. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
13. Lee J-M, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014;106.
14. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 doseescalation trial. Lancet Oncol 2013;14:882-92.
15. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012;18:1726-34.
16. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 2013;71:1191-9.
17. Stachelek GC, Dalal S, Donigan KA, Campisi Hegan D, Sweasy JB, Glazer PM. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. Cancer Res 2010;70: 409-17.
18. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-90.
19. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997;57:2933-6.
20. Hehlgans S, Storch K, Lange I, Cordes N. The novel HDAC inhibitor NDACI054 sensitizes human cancer cellstoradiotherapy. Radiother Oncol 2013;109:126-32.
21. Levitt RJ, Georgescu MM, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 2005;336:1056-61.
22. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009;69:6381-6.
23. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999;4:1093-9
24. Gunn A, Stark JM. I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks. Methods Mol Biol 2012;920:379-91.
25. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999;13:2633-8.
26. Chernikova SB, Wells RL, Elkind MM. Wortmannin sensitizes mammalian cells to radiation by inhibiting the DNA-dependent protein kinase-mediated rejoining of double-strand breaks. Radiat Res 1999;151:159-66.
27. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010;70:4972-81.
28. Taverna P, Hwang HS, Schupp JE, Radivoyevitch T, Session NN, Reddy G, et al. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res 2003;63:838-46.
29. Chou TC, Talalay P. Generalized equations forthe analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115:207-16.
30. Lin C, Yu Y, Zhao HG, Yang A, Yan H, Cui Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol 2012;104:395-400.
31. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;177:1053-64.
32. Matsuda A, Katanoda K. Five-year relative survival rate of ovarian cancer in the USA, Europe, and Japan. Jpn J Clin Oncol 2014;44:196.
33. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9.
34. Leahy JJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L, et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett 2004;14:6083-7.
35. Dupre A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 2008;4:119-25.
36. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011;7:428-30.